ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

ChemoCentryx announced that CEO Thomas J. Schall will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 5:00 p.m. ET. A live webcast will be available on the company’s website, with a replay accessible for two weeks post-event. ChemoCentryx focuses on developing therapies for inflammatory, autoimmune diseases, and cancer, and markets TAVNEOS®, an approved treatment for ANCA-associated vasculitis. For further details, please visit www.chemocentryx.com.

SAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 11^th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16^th at 5:00 p.m. Eastern Time.

A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. A replay of the webcast will be available on the Company's website for two weeks following the live presentation.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the United States, ChemoCentryx markets TAVNEOS^® (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. For more information about the Company visit www.chemocentryx.com.

TAVNEOS^® is a registered trademark of ChemoCentryx, Inc. For more information, please see the Full Prescribing Information and Medication Guide, available at TAVNEOS.com.

Contacts
Investors:
Bill Slattery, Jr.
Vice President, Investor Relations
and Corporate Communications
650.210.2970
bslattery@chemocentryx.com

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

 

FAQ

What is the date of ChemoCentryx's participation in the SVB Leerink Global Healthcare Conference?

ChemoCentryx will participate in the SVB Leerink Global Healthcare Conference on February 16, 2022.

Who will represent ChemoCentryx at the conference?

Thomas J. Schall, Ph.D., the President and CEO of ChemoCentryx, will represent the company.

Where can I watch the ChemoCentryx conference presentation?

The presentation can be accessed via a live webcast on the Investors section of ChemoCentryx's website.

How long will the webcast of the ChemoCentryx presentation be available?

A replay of the webcast will be available for two weeks following the live presentation.

What is TAVNEOS, marketed by ChemoCentryx?

TAVNEOS® is the first approved orally-administered inhibitor for treating ANCA-associated vasculitis.